Research programme: mitochondrial function stimulants - MitoChem Therapeutics
Latest Information Update: 16 Jul 2016
At a glance
- Originator MitoChem Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal-disorders in USA (Ophthalmic, Drops)
- 02 Mar 2012 Preclinical trials in Retinal disorders in USA (Ophthalmic)
- 31 Dec 2009 Early research in Retinal disorders in USA (Ophthalmic)